(SUPN) Supernus Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8684591089
SUPN: Epilepsy, Migraine, ADHD, Parkinson's, Seizures, Depression
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) operates in the biopharmaceutical sector, concentrating on central nervous system (CNS) disorders. Their product lineup includes Trokendi XR and Oxtellar XR, both extended-release formulations for epilepsy and migraines, showcasing their focus on seizure disorders.
Recent expansion includes Qelbree, a non-stimulant ADHD treatment, and GOCOVRI for Parkinsons dyskinesia, indicating a strategic move into broader CNS applications. Their Parkinsons portfolio is enhanced by XADAGO and APOKYN, addressing off episodes, along with MYOBLOC for cervical dystonia and Osmolex ER for extrapyramidal reactions.
Their pipeline highlights late-stage candidates like SPN-830 for Parkinsons and Phase II trials for SPN-817 and SPN-820, targeting epilepsy and depression respectively. Early-stage projects like SPN-443 and SPN-448 show potential in ADHD and CNS disorders, demonstrating a commitment to innovation.
With a market cap of ~$2.18B, SUPN trades at a P/E of 36.94, reflecting strong earnings expectations. Their infrastructure, including partnerships with wholesalers and specialty pharmacies, supports efficient distribution, aligning with their strategic growth objectives.
Headquartered in Rockville, Maryland since 2005, Supernus Pharmaceuticals continues to evolve, focusing on CNS treatments with a robust pipeline and strategic product launches. For more details, visit their website at https://www.supernus.com.
Additional Sources for SUPN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SUPN Stock Overview
| Market Cap in USD | 1,833m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2012-05-01 |
SUPN Stock Ratings
| Growth 5y | 61.0% |
| Fundamental | 41.9% |
| Dividend | 0.0% |
| Rel. Strength Industry | -9.86 |
| Analysts | 4.2/5 |
| Fair Price Momentum | 29.92 USD |
| Fair Price DCF | 70.89 USD |
SUPN Dividends
No Dividends PaidSUPN Growth Ratios
| Growth Correlation 3m | -26.1% |
| Growth Correlation 12m | 65% |
| Growth Correlation 5y | 58.1% |
| CAGR 5y | 15.68% |
| CAGR/Max DD 5y | 0.34 |
| Sharpe Ratio 12m | 0.08 |
| Alpha | -17.85 |
| Beta | 0.89 |
| Volatility | 35.29% |
| Current Volume | 781.7k |
| Average Volume 20d | 747.8k |
As of March 14, 2025, the stock is trading at USD 31.17 with a total of 781,745 shares traded.
Over the past week, the price has changed by -2.04%, over one month by -21.15%, over three months by -13.82% and over the past year by -10.07%.
Partly, yes. Based on ValueRay Fundamental Analyses, Supernus Pharmaceuticals (NASDAQ:SUPN) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 41.89 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SUPN as of March 2025 is 29.92. This means that SUPN is currently overvalued and has a potential downside of -4.01%.
Supernus Pharmaceuticals has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy SUPN.
- Strong Buy: 3
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, SUPN Supernus Pharmaceuticals will be worth about 33.5 in March 2026. The stock is currently trading at 31.17. This means that the stock has a potential upside of +7.48%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 38.8 | 24.5% |
| Analysts Target Price | 42.8 | 37.3% |
| ValueRay Target Price | 33.5 | 7.5% |